Investigating the pathophysiological importance of the molecular and mechanical development of cardiomyopathy is critical to find new and broader means of protection against this disease that is increasing in prevalence and impact. The current available treatment options for cardiomyopathy mainly focus on treating symptoms and strive to make the patient more comfortable while preventing progression of disease and sudden death. The proto-oncogene c-Myc (Myc) has been shown to be increased in many different types of heart disease, including hypertrophic cardiomyopathy, before any signs of the disease are present. As the mechanisms of action and multiple pathways of dependent actions of Myc are being dissected by many research groups, inhibition of Myc is becoming an attractive paradigm for prevention and treatment of cardiomyopathy and heart failure. Elucidating the role Myc plays in the development, propagation and perpetuation of cardiomyopathy and heart failure will one day translate into potential therapeutics for cardiomyopathy.
AgarwalS.S.ChoksiC.SheikhI. (2004) Sudden death – a case of hypertrophic cardiomyopathy. J Indian Acad Forensic Med26: 157–159.
2.
AndersonP.A.GreigA.MarkT.M.MaloufN.N.OakeleyA.E.UngerleiderR.M. (1995) Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res76: 681–686.
3.
BaartscheerA.van BorrenM.M. (2008) Sodium ion transporters as new therapeutic targets in heart failure. Cardiovasc Hematol Agents Med Chem6: 229–236.
4.
BarryS.P.DavidsonS.M.TownsendP.A. (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol40: 2023–2039.
5.
BasileJ.TothP.P. (2009) Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J102(10, Suppl.): S1–S12.
6.
Bello RoufaiM.LiH.SunZ. (2007) Heart-specific inhibition of protooncogene c-Myc attenuates cold-induced cardiac hypertrophy. Gene Ther14: 1406–1416.
7.
BennettM.R.LindnerV.DeBloisD.ReidyM.A.SchwartzS.M. (1997) Effect of phosphorothioated oligonucleotides on neointima formation in the rat carotid artery. Dissecting the mechanism of action. Arterioscler Thromb Vasc Biol17: 2326–2332.
8.
BernhardD.LauferG. (2008) The aging cardiomyocyte: a mini-review. Gerontology54: 24–31.
9.
BraunwaldE.SeidmanC.E.SigwartU. (2002) Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation106: 1312–1316.
10.
BrophyJ.M.JosephL.RouleauJ.L. (2001) Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med134: 550–560.
11.
CaiH.HarrisonD.G. (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res87: 840–844.
12.
CelikT.YukselC.IyisoyA. (2010) Alpha tocopherol use in the management of diabetic cardiomyopathy: lessons learned from randomized clinical trials. J Diabetes Complications24: 286–288.
13.
ChandraM.RundellV.L.TardiffJ.C.LeinwandL.A.De TombeP.P.SolaroR.J. (2001) Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol280: H705–H713.
14.
ChenS.SuJ.WuK.HuW.GardnerD.G.ChenD. (1998) Early captopril treatment prevents hypertrophydependent gene expression in hearts of SHR. Am J Physiol274: R1511–R1517.
15.
ClaassenG.F.HannS.R. (1999) Myc-mediated transformation: the repression connection. Oncogene18: 2925–2933.
16.
CoatsC.J.HollmanA. (2008) Hypertrophic cardiomyopathy: lessons from history. Heart94: 1258–1263.
17.
CONSENSUS Trial Study Group. (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med316: 1429–1435.
18.
DangC.V.LiF.LeeL.A. (2005) Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?Cell Cycle4: 1465–1466.
19.
DeboldE.P.SchmittJ.P.PatlakJ.B.BeckS.E.MooreJ.R.SeidmanJ.G. (2007) Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol293: H284–H291.
20.
DecG.W.FusterV. (1994) Idiopathic dilated cardiomyopathy. N Engl J Med331: 1564–1575.
21.
DiezJ.PanizoA.HernandezM.GalindoM.F.CenarruzabeitiaE.Pardo MindanF.J. (1997) Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats. Am J Hypertens10: 1147–1152.
22.
Digitalis Investigation Group. (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med336: 525–533.
23.
DzimiriN.Al-BahnasiK.Al-HaleesZ. (2004) Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload. Fundam Clin Pharmacol18: 39–44.
24.
ElahiM.M.MatataB.M. (2006) Free radicals in blood: evolving concepts in the mechanism of ischemic heart disease. Arch Biochem Biophys450: 78–88.
25.
EpsteinN.D.CohnG.M.CyranF.FananapazirL. (1992) Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu→Val mutation and a 403Arg→Gln mutation. Circulation86: 345–352.
26.
ErdmannJ.DaehmlowS.WischkeS.SenyuvaM.WernerU.RaibleJ. (2003) Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet64: 339–349.
27.
FokstuenS.LyleR.MunozA.GehrigC.LerchR.PerrotA. (2008) A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat29: 879–885.
FrankD.KuhnC.BrorsB.HanselmannC.LuddeM.KatusH.A. (2008) Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program. Hypertension51: 309–318.
30.
FreudeB.MastersT.N.RobicsekF.FokinA.KostinS.ZimmermannR. (2000) Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol32: 197–208.
31.
Geisterfer-LowranceA.A.KassS.TanigawaG.VosbergH.P.McKennaW.SeidmanC.E. (1990) A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell62: 999–1006.
32.
GemayelC.PellicciaA.ThompsonP.D. (2001) Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol38: 1773–1781.
33.
GheorghiadeM.van VeldhuisenD.J.ColucciW.S. (2006) Contemporary use of digoxin in the management of cardiovascular disorders. Circulation113: 2556–2564.
34.
GilbertR.KellyM.G.MikawaT.FischmanD.A. (1996) The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Sci109: 101–111.
GoldbergerJ.J.CainM.E.HohnloserS.H.KadishA.H.KnightB.P.LauerM.S. (2008) American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Heart Rhythm5: e1–e21.
37.
GolfS.MyhreE.AbdelnoorM.AndersenD.HanssonV. (1985) Hypertrophic cardiomyopathy characterised by beta-adrenoceptor density, relative amount of beta-adrenoceptor subtypes and adenylate cyclase activity. Cardiovasc Res19: 693–699.
38.
GoodfellowS.J.InnesF.DerblayL.E.MacLellanW.R.ScottP.H.WhiteR.J. (2006) Regulation of RNA polymerase III transcription during hypertrophic growth. EMBO J25: 1522–1533.
39.
GustafssonA.B.GottliebR.A. (2008) Heart mitochondria: gates of life and death. Cardiovasc Res77: 334–343.
40.
GysinR.AzziA.VisariusT. (2002) Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J16: 1952–1954.
41.
HanH.J.HanJ.Y.HeoJ.S.LeeS.H.LeeM.Y.KimY.H. (2007) ANG II-stimulated DNA synthesis is mediated by ANG II receptor-dependent Ca(2+)/PKC as well as EGF receptor-dependent PI3K/Akt/mTOR/p70S6K1 signal pathways in mouse embryonic stem cells. J Cell Physiol211: 618–629.
42.
HartzellH.C. (1985) Effects of phosphorylated and unphosphorylated C-protein on cardiac actomyosin ATPase. J Mol Biol186: 185–195.
43.
HellmanU.MornerS.Engstrom-LaurentA.SamuelJ.L.WaldenstromA. (2010) Temporal correlation between transcriptional changes and increased synthesis of hyaluronan in experimental cardiac hypertrophy. Genomics96: 73–81.
44.
HimedaC.L.RanishJ.A.HauschkaS.D. (2008) Quantitative proteomic identification of MAZ as a transcriptional regulator of muscle-specific genes in skeletal and cardiac myocytes. Mol Cell Biol28: 6521–6535.
45.
HirotaH.ChenJ.BetzU.A.RajewskyK.GuY.RossJ.Jr (1999) Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell97: 189–198.
46.
HofmannP.A.HartzellH.C.MossR.L. (1991) Alterations in Ca2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol97: 1141–1163.
47.
HuangC.Y.FujimuraM.NoshitaN.ChangY.Y.ChanP.H. (2001) SOD1 down-regulates NF-kappaB and c-Myc expression in mice after transient focal cerebral ischemia. J Cereb Blood Flow Metab21: 163–173.
48.
HuntS.A.AbrahamW.T.ChinM.H.FeldmanA.M.FrancisG.S.GaniatsT.G. (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation119: e391–e479.
49.
JacksonT.AllardM.F.SreenanC.M.DossL.K.BishopS.P.SwainJ.L. (1990) The c-Myc proto-oncogene regulates cardiac development in transgenic mice. Mol Cell Biol10: 3709–3716.
50.
JarchoJ.A.McKennaW.PareJ.A.SolomonS.D.HolcombeR.F.DickieS. (1989) Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med321: 1372–1378.
JessupM.AbrahamW.T.CaseyD.E.FeldmanA.M.FrancisG.S.GaniatsT.G. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation119: 1977–2016.
53.
JoglarJ.A.AcustaA.P.ShustermanN.H.RamaswamyK.KowalR.C.BarberaS.J. (2001) Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J142: 498–501.
54.
KaiH.MuraishiA.SugiuY.NishiH.SekiY.KuwaharaF. (1998) Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res83: 594–601.
55.
Kaneko-IshinoT.KumeT.U.SasakiH.ObinataM.OishiM. (1988) Effect of c-Myc gene expression on early inducible reactions required for erythroid differentiation in vitro. Mol Cell Biol8: 5545–5548.
56.
KatragaddaS.AroraR.R. (2010) Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther17: e11–e23.
57.
KipshidzeN.KeaneE.SteinD.ChawlaP.SkrinskaV.ShankarL.R. (2001) Local delivery of c-Myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv54: 247–256.
58.
KostisJ.B.SheltonB.GosselinG.GouletC.HoodW.B.JrKohnR.M. (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J131: 350–355.
59.
KushwahaS.S.FallonJ.T.FusterV. (1997) Restrictive cardiomyopathy. N Engl J Med336: 267–276.
60.
KwonS.H.PimentelD.R.RemondinoA.SawyerD.B.ColucciW.S. (2003) H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol35: 615–621.
61.
LachmanH.M.ChengG.H.SkoultchiA.I. (1986) Transfection of mouse erythroleukemia cells with Myc sequences changes the rate of induced commitment to differentiate. Proc Natl Acad Sci U S A83: 6480–6484.
62.
LancisiG. (1728) De motu cordis et aneurysmatibus, Rome: Apud Joannem Mariam Salvioni.
63.
LandmesserU.HarrisonD.G. (2001) Oxidative stress and vascular damage in hypertension. Coron Artery Dis12: 455–461.
64.
LeeH.G.ChenQ.WolframJ.A.RichardsonS.L.LinerA.SiedlakS.L. (2009) Cell cycle re-entry and mitochondrial defects in Myc-mediated hypertrophic cardiomyopathy and heart failure. PLoS One4: e7172–e7172.
65.
LijnenP.PetrovV. (1999) Antagonism of the renin–angiotensin system, hypertrophy and gene expression in cardiac myocytes. Methods Find Exp Clin Pharmacol21: 363–374.
66.
LowesB.D.GilbertE.M.AbrahamW.T.MinobeW.A.LarrabeeP.FergusonD. (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med346: 1357–1365.
67.
LoweyS. (2002) Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. Trends Cardiovasc Med12: 348–354.
68.
MarianA.J.WuY.LimD.S.McCluggageM.YoukerK.YuQ.T. (1999) A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest104: 1683–1692.
69.
MaronB.J.ShenW.K.LinkM.S.EpsteinA.E.AlmquistA.K.DaubertJ.P. (2000) Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med342: 365–373.
70.
MaronB.J.BonowR.O.SalbergL.RobertsW.C.BraunwaldE. (2008) The first patient clinically diagnosed with hypertrophic cardiomyopathy. Am J Cardiol102: 1418–1420.
71.
MaronB.J.MaronM.S.WigleE.D.BraunwaldE. (2009) The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol54: 191–200.
MohiddinS.A.BegleyD.A.McLamE.CardosoJ.P.WinklerJ.B.SellersJ.R. (2003) Utility of genetic screening in hypertrophic cardiomyopathy: prevalence and significance of novel and double (homozygous and heterozygous) beta-myosin mutations. Genet Test7: 21–27.
74.
NapoliC.LermanL.O.de NigrisF.SicaV. (2002) c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?Neoplasia4: 185–190.
75.
NieminenA.I.PartanenJ.I.KlefstromJ. (2007) c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle6: 2464–2472.
76.
NiimuraH.BachinskiL.L.SangwatanarojS.WatkinsH.ChudleyA.E.McKennaW. (1998) Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med338: 1248–1257.
77.
NishimuraR.A.HayesD.L.IlstrupD.M.HolmesD.R.JrTajikA.J. (1996) Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol27: 421–430.
78.
OberstL.ZhaoG.ParkJ.T.BrugadaR.MichaelL.H.EntmanM.L. (1998) Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest102: 1498–1505.
79.
OrlovS.N.PchejetskiD.V.SarkissianS.D.AdarichevV.TaurinS.PshezhetskyA.V. (2003) [3H]-Thymidine labelling of DNA triggers apoptosis potentiated by E1A-adenoviral protein. Apoptosis8: 199–208.
80.
PerrotA.Schmidt-TraubH.HoffmannB.PragerM.Bit-AvragimN.RudenkoR.I. (2005) Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Mol Med83: 468–477.
81.
PfefferM.A.BraunwaldE.MoyeL.A.BastaL.BrownE.J.JrCuddyT.E. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med327: 669–677.
82.
PucciB.KastenM.GiordanoA. (2000) Cell cycle and apoptosis. Neoplasia2: 291–299.
83.
RawlesJ.M.MetcalfeM.J.JenningsK. (1990) Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J63: 225–227.
84.
RichardP.CharronP.CarrierL.LedeuilC.CheavT.PichereauC. (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation107: 2227–2232.
85.
RiuE.BoschF.ValeraA. (1996) Prevention of diabetic alterations in transgenic mice overexpressing Myc in the liver. Proc Natl Acad Sci U S A93: 2198–2202.
86.
SabbahH.N. (2004) Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev9: 91–97.
87.
SabbahH.N.SharovV.G. (1998) Apoptosis in heart failure. Prog Cardiovasc Dis40: 549–562.
88.
SabbahH.N.SharovV.G.GuptaR.C.TodorA.SinghV.GoldsteinS. (2000) Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol36: 1698–1705.
89.
ShiY.FardA.GaleoA.HutchinsonH.G.VermaniP.DodgeG.R. (1994) Transcatheter delivery of c-Myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation90: 944–951.
90.
SmithT.W. (1988) Digitalis. Mechanisms of action and clinical use. N Engl J Med318: 358–365.
91.
SoleM.J.LiewC.C. (1988) Catecholamines, calcium and cardiomyopathy. Am J Cardiol62: 20G–24G.
92.
SOLVD Investigators. (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med327: 685–691.
93.
St John SuttonM.G.LieJ.T.AndersonK.R.O’BrienP.C.FryeR.L. (1980) Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J44: 433–443.
94.
StarksenN.F.SimpsonP.C.BishopricN.CoughlinS.R.LeeW.M.EscobedoJ.A. (1986) Cardiac myocyte hypertrophy is associated with c-Myc protooncogene expression. Proc Natl Acad Sci U S A83: 8348–8350.
95.
SuJ.Z.ChenD.G.WuK.G.ChenS.C.HuW.Y.WangX.Y. (1998) Inhibitory effects of captopril on c-Myc expression during left ventricular hypertrophy. Zhongguo Yao Li Xue Bao19: 535–540.
96.
TarolliK.A. (2003) Left ventricular systolic dysfunction and nonischemic cardiomyopathy. Crit Care Nurs Q26: 3–15.
97.
TeareD. (1958) Asymmetrical hypertrophy of the heart in young adults. Br Heart J20: 1–8.
98.
TrenerryM.K.CareyK.A.WardA.C.Cameron-SmithD. (2007) STAT3 signaling is activated in human skeletal muscle following acute resistance exercise. J Appl Physiol102: 1483–1489.
99.
TyskaM.J.HayesE.GiewatM.SeidmanC.E.SeidmanJ.G.WarshawD.M. (2000) Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res86: 737–744.
100.
VafaO.WadeM.KernS.BeecheM.PanditaT.K.HamptonG.M. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell9: 1031–1044.
101.
VasanR.S.BenjaminE.J.LevyD. (1995) Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol26: 1565–1574.
102.
WadhawanR.TsengY.T.StabilaJ.McGonnigalB.SarkarS.PadburyJ. (2003) Regulation of cardiac beta 1-adrenergic receptor transcription during the developmental transition. Am J Physiol Heart Circ Physiol284: H2146–H2152.
103.
WatkinsH.AnanR.CovielloD.A.SpiritoP.SeidmanJ.G.SeidmanC.E. (1995a) A de novo mutation in alpha-tropomyosin that causes hypertrophic cardiomyopathy. Circulation91: 2302–2305.
104.
WatkinsH.McKennaW.J.ThierfelderL.SukH.J.AnanR.O’DonoghueA. (1995b) Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med332: 1058–1064.
105.
WhiteP.D.BoursyA. (1971) Translation of Giovanni Maria Lancisi’s book De subitaneis mortibus libri duo (Rome, 1707), New York: St John’s University Press.
106.
WieczorekD.F.JagatheesanG.RajanS. (2008) The role of tropomyosin in heart disease. Adv Exp Med Biol644: 132–142.
107.
XiaoG.MaoS.BaumgartenG.SerranoJ.JordanM.C.RoosK.P. (2001) Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res89: 1122–1129.
ZhongW.MaoS.TobisS.AngelisE.JordanM.C.RoosK.P. (2006) Hypertrophic growth in cardiac myocytes is mediated by Myc through a cyclin D2-dependent pathway. EMBO J25: 3869–3879.
112.
ZhuZ.ZhuS.LiuD.YuZ.YangY.van der GietM. (2005) GATA4-mediated cardiac hypertrophy induced by d-myo-inositol 1,4,5-tris-phosphate. Biochem Biophys Res Commun338: 1236–1240.
